ArticleCancer discovery2020
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 109 papers.
0numbers the graph read from it
0cells of the map it votes in
109citing papers in PubMed
10.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
109 citing papers in PubMed, 168 citations in OpenAlex.
- Association between Locoregional Failure and NFE2L2/KEAP1/CUL3 Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- A USP8-targeting nanoamplifier synergizes with radiotherapy to remodel the immunosuppressive tumor microenvironment in lung cancer.Materials today. Bio · 2026Article
- Gambogenic acid globally regulates translational processes in Nrf2-mutant esophageal squamous cell carcinoma by promoting Nrf2/MafG protein multimerization.Acta pharmacologica Sinica · 2026Article
- LncRNANAR cancer · 2026Article
- A targetable FTO/SLC7A11/CBS/CTH axis controls cysteine metabolism, growth and survival in NSCLC.Science advances · 2026Article
- Biomarkers of radioresistance in lung cancer: Current insights and future directions (Review).Molecular medicine reports · 2026Review
- Beyond KEAP1: The Context-Specific NRF2 Partner Code in Disease and Therapy.Antioxidants (Basel, Switzerland) · 2026Review
- GLUT6-facilitated noncanonical glucose metabolic rewiring enables resistance to targeted cancer therapy.Nature communications · 2026Article
- IFN signaling is associated with radiotherapy response in malignant peripheral nerve sheath tumors.The Journal of clinical investigation · 2026Article
- The consensus molecular subtypes of esophageal squamous cell carcinoma.Signal transduction and targeted therapy · 2026Article
- TheCancer management and research · 2026Review
- Cancer metabolism: from the Warburg effect to precision therapy.Frontiers in immunology · 2026Review
- Hypoxic tumor exosomes suppress macrophage inflammation and ferroptosis via NDUFV2 to enhance bystander tumor radioresistance.Cell death & disease · 2025Article
- Impact of RAS-MAPK Pathway Genetic Alterations on Radiotherapy Response in Metastatic Lung Adenocarcinoma.JCO precision oncology · 2025Article
- Survival impact of a KEAP1-NFE2L2 radiomics model in PDL1 ≥ 50% non-small cell lung cancer treated with pembrolizumab: the PEMBROMIC study.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Nuclear Factor Erythroid 2-Related Factor 2 (NRF2) as a Biomarker for Radiation Dosimetry and Health Risk Assessment: A Review.Antioxidants (Basel, Switzerland) · 2025Review
- Oncogenic NFE2L2 mutations in plasma ctDNA and tumors are predictors and prognosticators of chemoradiation therapy in resectable esophageal squamous cell carcinoma.British journal of cancer · 2025Article
- NRF2 immunobiology in cancer: implications for immunotherapy and therapeutic targeting.Oncogene · 2025Review
- Integrating ctDNA Analysis and Radiomics for Dynamic Risk Assessment in Localized Lung Cancer.Cancer discovery · 2025Article
- Involvement of KEAP1/NRF2 pathway in non-BRAF mutated squamous cell carcinoma of the thyroid.The Journal of pathology · 2025Article
49 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 4 institutions in 3 countries.
Michael S Binkley *Department of Radiation Oncology, Stanford University, Stanford, California.
Young-Jun Jeon *Stanford Cancer Institute, Stanford, California.ORCID https://orcid.org/0000-0002-5998-9605
Monica NesselbushCancer Biology Program, Stanford University, Stanford, California.ORCID https://orcid.org/0000-0003-4818-2301
Everett J ModingDepartment of Radiation Oncology, Stanford University, Stanford, California.ORCID https://orcid.org/0000-0001-7913-5351
Barzin Y NabetDepartment of Radiation Oncology, Stanford University, Stanford, California.ORCID https://orcid.org/0000-0002-4824-3533
Diego AlmanzaCancer Biology Program, Stanford University, Stanford, California.
Christian KunderDepartment of Pathology, Stanford University, Stanford, California.ORCID https://orcid.org/0000-0003-1514-7550
Henning StehrDepartment of Pathology, Stanford University, Stanford, California.
Christopher H YooDepartment of Radiation Oncology, Stanford University, Stanford, California.ORCID https://orcid.org/0000-0003-2132-8956
Siyeon RheeDepartment of Biology, Stanford University, Stanford, California.ORCID https://orcid.org/0000-0002-7642-4016
Michael XiangDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, California.
Jacob J ChabonStanford Cancer Institute, Stanford, California.
Emily HamiltonCancer Biology Program, Stanford University, Stanford, California.
David M KurtzDivision of Oncology, Department of Medicine, Stanford University, Stanford, California.ORCID https://orcid.org/0000-0002-6382-4651
Linda GojenolaDepartment of Pathology, Stanford University, Stanford, California.
Susie Grant OwenDepartment of Radiation Oncology, Stanford University, Stanford, California.
Ryan B KoDepartment of Radiation Oncology, Stanford University, Stanford, California.ORCID https://orcid.org/0000-0002-2123-9702
June Ho ShinStanford Cancer Institute, Stanford, California.
Peter G MaximDepartment of Radiation Oncology, Stanford University, Stanford, California.ORCID https://orcid.org/0000-0002-8244-2042
Natalie S LuiDivision of Thoracic Surgery, Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, California.
Leah M BackhusDivision of Thoracic Surgery, Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, California.
Mark F BerryDivision of Thoracic Surgery, Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, California.
Joseph B ShragerDivision of Thoracic Surgery, Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, California.
Kavitha J RamchandranStanford Cancer Institute, Stanford, California.
Sukhmani K PaddaStanford Cancer Institute, Stanford, California.
Millie DasStanford Cancer Institute, Stanford, California.
Joel W NealStanford Cancer Institute, Stanford, California.
Heather A WakeleeStanford Cancer Institute, Stanford, California.ORCID https://orcid.org/0000-0003-1136-980X
Ash A AlizadehStanford Cancer Institute, Stanford, California.
Billy W LooDepartment of Radiation Oncology, Stanford University, Stanford, California.
Maximilian DiehnDepartment of Radiation Oncology, Stanford University, Stanford, California. diehn@stanford.edu.ORCID https://orcid.org/0000-0003-2032-0581
Cancer Prevention Institute of California · USStanford Medicine · USStanford University · USUniversity of California, Los Angeles · US
Funding
Leveraging innovative technologies in basic and clinical cancer researchT32CA009302 · NCI · STANFORD UNIVERSITY · PI LAURA D ATTARDI, Aaron M Newman · 1985 to 2026
$19.1MMolecularly-based outcome and toxicity prediction after radiotherapy for lung cancerR01CA254179 · NCI · STANFORD UNIVERSITY · PI ALIZADEH, ASH ARASH, DIEHN, MAXIMILIAN · 2020 to 2024
$3.1MA Genomic Framework for Molecular Risk Prediction & Individualized Lymphoma TherapyR01CA233975 · NCI · STANFORD UNIVERSITY · PI ALIZADEH, ASH ARASH, DIEHN, MAXIMILIAN · 2019 to 2023
$2.8MDeveloping a genomic approach for cancer screeningDP2CA186569 · NCI · STANFORD UNIVERSITY · PI DIEHN, MAXIMILIAN · 2013 to 2013
$2.4MPostdoctoral Training in the Radiation ScincesT32CA121940 · NCI · STANFORD UNIVERSITY · PI GRAVES, EDWARD E. · 2007 to 2018
$2.1MNoninvasive monitoring of lung cancer patients treated with radiotherapyR01CA188298 · NCI · STANFORD UNIVERSITY · PI ALIZADEH, ASH ARASH, DIEHN, MAXIMILIAN · 2015 to 2019
$1.8MNCI NIH HHS DP2 CA186569NCI NIH HHS R01 CA188298NCI NIH HHS R01 CA233975NCI NIH HHS R01 CA254179NCI NIH HHS T32 CA009302NCI NIH HHS T32 CA121940
Abstract
Tumor genotyping is not routinely performed in localized non-small cell lung cancer (NSCLC) due to lack of associations of mutations with outcome. Here, we analyze 232 consecutive patients with localized NSCLC and demonstrate that
Indexed as
BiomarkersGlutaminaseHumansKelch-Like ECH-Associated Protein 1Lung NeoplasmsMutationNF-E2-Related Factor 2Radiation ToleranceBiomarkersGlutaminaseKEAP1 protein, humanKelch-Like ECH-Associated Protein 1NF-E2-Related Factor 2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.